Metaculus Help: Spread the word
If you like Metaculus, tell your friends! Share this question via Facebook, Twitter, or Reddit.
Will a RNA SARS-CoV-2 vaccine candidate be approved for use in the United States or European Union before 2022?
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is a novel betacoronavirus that likely emerged late last year from an animal reservoir in China. There is little to no pre-existing immunity against it in the human population. The clinical picture for the disease it causes, coronavirus disease 2019 (COVID-19), ranges from very mild to fatal. The virus is highly transmissible and has spread globally.
As of 20 March 2020, the WHO (World Health Organization) is reporting that it is tracking the development of forty-four SARS-CoV-2 candidate vaccines. Two of these candidates have entered phase one and the other forty-two remain in the pre-clinical stage. One of the candidates in phase one is a RNA vaccine candidate, as are seven of the candidates in the pre-clinical stage.
RNA vaccines are of particular interest because they can be developed and produced relatively quickly since, unlike other vaccine platforms, they do not require fermentation or culture and instead use faster synthetic processes. As a result, the first SARS-CoV-2 vaccine candidate to enter a phase one clinical trial is a RNA vaccine, mRNA-1273, which was developed by Moderna Therapeutics at record speed.
While promising, RNA-based vaccine platforms are a new development and the field is still nascent. No RNA vaccine has ever made it to market. And since no RNA vaccine has been approved to date, there is an urgent need to determine the likelihood of successful development of such a vaccine for SARS-CoV-2.
This question asks: Will a RNA SARS-CoV-2 vaccine candidate be approved for use in the United States or European Union before 2022?
Resolution will be determined via the first relevant press release made by the FDA, EMA, or European Commission regarding the approval of a RNA SARS-CoV-2 vaccine candidate. In the United States, approval means that the vaccine candidate has been licensed by the FDA. In the European Union, approval means that the EMA has recommended the vaccine candidate for approval and the European Commission has granted that approval via marketing authorization. Approval under any other emergency procedures, such as expanded access, would not count.
Metaculus help: Predicting
Predictions are the heart of Metaculus. Predicting is how you contribute to the wisdom of the crowd, and how you earn points and build up your personal Metaculus track record.
The basics of predicting are very simple: move the slider to best match the likelihood of the outcome, and click predict. You can predict as often as you want, and you're encouraged to change your mind when new information becomes available.
The displayed score is split into current points and total points. Current points show how much your prediction is worth now, whereas total points show the combined worth of all of your predictions over the lifetime of the question. The scoring details are available on the FAQ.
Note: this question resolved before its original close time. All of your predictions came after the resolution, so you did not gain (or lose) any points for it.
Note: this question resolved before its original close time. You earned points up until the question resolution, but not afterwards.
This question is not yet open for predictions.
Metaculus help: Community Stats
Use the community stats to get a better sense of the community consensus (or lack thereof) for this question. Sometimes people have wildly different ideas about the likely outcomes, and sometimes people are in close agreement. There are even times when the community seems very certain of uncertainty, like when everyone agrees that event is only 50% likely to happen.
When you make a prediction, check the community stats to see where you land. If your prediction is an outlier, might there be something you're overlooking that others have seen? Or do you have special insight that others are lacking? Either way, it might be a good idea to join the discussion in the comments.